Reporte zur Charge UI691AA

Symptomtext

swelling in the back of throat and nasopharyngeal area; myalgia; chills; fever; malaise; Initial information regarding an unsolicited valid non-serious case was received from a consumer via The Agency (Reference number- 00416318) on 05-Jan-2021. The case involved a female patient of unknown age who experienced swelling in the back of throat and nasopharyngeal area (pharyngeal swelling), myalgia, chills, fever (pyrexia) and malaise, while she received INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HD]. Relevant medical history, past medical treatment, vaccination details, concomitant medications and family history were not provided. On an unknown date in 2016, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot UI691AA, expiry date not reported) via unknown route in unknown administration site for prophylactic vaccination. On an unknown date, the patient developed non-serious significant reactions of swelling in the back of throat and nasopharyngeal area (pharyngeal swelling), myalgia, chills, fever (pyrexia) and malaise, unknown latency following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE. The patient had not received a flu vaccine since. Now that she had to get a Covid vaccine, the patient wanted to know what agents in the vaccine might possibly had caused the reaction so that she could avoid those things in the Covid vaccine if possible. The doctor only listed the name and she assumed lot number above and told the patient to contact you for more specific information. Relevant laboratory test was not reported. It was not reported if the patient received any corrective treatment. At the time of reporting, the outcome was unknown for the reported events.